The United Kingdom and the United States have forged a significant commercial pact that will ensure no tariffs on British pharmaceutical exports entering the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has committed to raise spending on pharmaceuticals through the NHS. This pledge secures that tariffs on these crucial exports will remain at zero for a duration of the next three years.
This agreement comes after recent warnings to significantly raise import taxes on branded drug products, with potential rates mentioned reaching 100%.
"This agreement with the Britain bolsters the international landscape for new treatments and introduces much-needed equity to U.S.–U.K. medicine commerce," a release said.
Economic Importance
Pharmaceuticals represent one of the the United Kingdom's largest exports to the US, which is easily the biggest market for leading companies like GSK and AstraZeneca.
Export figures reveal that in the one-year period leading up to last September, the UK sold medicines valued at billions to the US. This figure accounted for 17.4% of British export trade in that period.
"This deal protects work, increases funding and facilitates the UK to establish itself as a global hub for medical research," the Business and Trade Secretary commented.
Key British Pledges
The agreement entails several specific changes from the United Kingdom:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a target to raise total health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The amount drug companies must pay back to the NHS to prevent overspending will be limited at 15%. Last year, refunds topped twenty percent.
Recent Tensions
This agreement comes amid a long-running row between the sector and the British authorities over spending levels and regulatory access.
The disagreement were exacerbated by assertions that American customers were paying significantly more for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or scrapped, while substantial funding commitments have been pledged toward American operations.
One official publicly accepted that the NHS had to spend more on drugs, noting that its expenditure on drugs had decreased as a share of its resources over the last ten years.
